Lineage Cell Therapeutics Inc (AMEX:LCTX)’s traded shares stood at 2.0 million during the last session, with the company’s beta value hitting 1.41. At the close of trading, the stock’s price was $0.60, to imply an increase of 18.27% or $0.09 in intraday trading. The LCTX share’s 52-week high remains $1.15, putting it -91.67% down since that peak but still an impressive 38.33% since price per share fell to its 52-week low of $0.37.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
After registering a 18.27% upside in the last session, Lineage Cell Therapeutics Inc (LCTX) has traded red over the past five days. The 5-day price performance for the stock is 28.48%, and 28.07% over 30 days. With these gigs, the year-to-date price performance is 20.30%.
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
The rating firms project that company’s revenue will shrink -34.57% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 1.48M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 1.57M.Earnings reports from the last fiscal year show that sales brought in 1.41M and 3.78M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 5.45% before dropping -58.45% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.93% for the past 5-year period. While 2025 is set for a 1.38% return in earnings, projections for the next 5 years are at -1.63% annually.
LCTX Dividends
Lineage Cell Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is BLACKROCK INC. with 9.56 million shares, or about 5.0629% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $9.53 million.
We also have iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Lineage Cell Therapeutics Inc (LCTX) shares. Going by data provided on Mar 31, 2025 , iShares Trust-iShares Russell 2000 ETF holds roughly 4.53 shares. This is just over 1.98% of the total shares, with a market valuation of $2.74 million. Data from the same date shows that the other fund manager holds a little less at 4.42, or 1.93% of the shares, all valued at about 2.67 million.
